| Title |
An interview with Dan L. Longo, Section Editor of the Malignant hematological diseases section
|
|---|---|
| Published in |
BMC Hematology, April 2013
|
| DOI | 10.1186/2052-1839-13-2 |
| Pubmed ID | |
| Authors |
Dan L Longo |
| Abstract |
Dan L. Longo is professor of medicine at Harvard Medical School in the division of hematology at Brigham and Women's Hospital and Deputy Editor of the New England Journal of Medicine. He is a Master of the American College of Physicians and is a member of the American Society of Clinical Investigation and the Association of American Physicians. He has been active in research on the treatment of malignant lymphoma including new treatments targeting CD30, CD40, HLA Class II molecules and immunoglobulin idiotype. His laboratory work has focused in part on the regulation of lymphocyte proliferation, NK cell effects on hematopoiesis, and tumor-induced immunosuppression. He is the Section Editor of the Malignant hematological diseases section for BMC Hematology. In this interview, he explains how he first became interested in hematology and gives his personal view on the recent progress and future challenges of the hematological cancer field in particular. |
Mendeley readers
The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 50% |
| Student > Bachelor | 1 | 25% |
| Student > Master | 1 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 75% |
| Unknown | 1 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2013.
All research outputs
#6,474,050
of 25,373,627 outputs
Outputs from BMC Hematology
#18
of 100 outputs
Outputs of similar age
#52,129
of 212,447 outputs
Outputs of similar age from BMC Hematology
#2
of 5 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 100 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,447 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.